New reports challenge the prosecution case on ‘Lucy Letby’
The prosecution case against Lucy Letby now faces fresh scrutiny from an international panel of medical experts and a formal Criminal Cases Review Commission application. Their February 2025 findings and subsequent filings argue that the original medical evidence does not support deliberate harm, reopening questions about conviction safety at a moment when the CCRC has confirmed it is actively assessing the material.
Panel composition and scope
Dr Shoo Lee assembled 26 international specialists whose 31 separate reports examined every case presented at trial. The panel reviewed clinical records, imaging, and laboratory results without relying on the prosecution narrative that had guided the original expert testimony.
Each reviewer worked independently before the group consolidated its conclusions. The process produced a single, uniform finding that no death or collapse showed signs of intentional injury.
Lee’s involvement carried added weight because his 1989 paper on pulmonary air embolism had been cited by the Crown; the panel argued that the paper’s criteria were applied incorrectly during the trial.
Medical conclusions reached
The experts determined that every incident resulted from natural disease processes or substandard care on the neonatal unit. They found no radiographic or pathological markers consistent with deliberate air injection or poisoning.
Insulin results flagged by the prosecution were re-examined in light of known limitations of the Roche immunoassay platform, which can produce falsely elevated readings in certain clinical contexts. The panel concluded these values did not prove exogenous administration.
Skin discolouration patterns once presented as diagnostic of air embolism were attributed to common neonatal conditions such as sepsis or circulatory collapse, none of which require external intervention.
CCRC application timeline
Letby’s legal team submitted the panel’s reports and supporting documents to the Criminal Cases Review Commission in February 2025. The CCRC acknowledged receipt and stated that assessment work had begun immediately.
Additional material filed later highlighted an undisclosed investigation into a key prosecution witness, paediatric endocrinologist Peter Hindmarsh, whose own clinical practices were under review at the time of his testimony.
The commission’s review remains ongoing into 2026, with no indication yet of when a decision on referral to the Court of Appeal will be reached.
Statistical evidence under review
Separate statistical analyses submitted alongside the medical reports question the weight given to shift-pattern correlations at trial. Commentators note that small sample sizes and multiple testing can produce misleading associations in hospital settings.
The Royal Statistical Society has previously warned against over-reliance on such data in medical-misconduct prosecutions, a caution now cited by Letby’s supporters.
These critiques do not replace the medical panel’s findings but add another layer of doubt about how circumstantial evidence was presented to the jury.
Witness credibility issues
Documents released in March 2026 show that Hindmarsh was subject to an internal hospital investigation during the period he gave evidence. The Crown has not commented on whether this information was disclosed to the defence before or during the trial.
Letby’s barrister, Mark McDonald, argues that the non-disclosure alone constitutes grounds for the CCRC to refer the case back to the Court of Appeal.
The issue has drawn attention from legal observers who track disclosure failures in complex medical prosecutions.
Hospital inquiry context
The Thirlwall Inquiry, established to examine Countess of Chester Hospital’s practices, is now expected to report no earlier than September 2026. Its remit excludes reassessment of the criminal convictions themselves.
Still, any findings on unit staffing, equipment failures, or infection control could provide further context for the panel’s conclusion that poor care, rather than deliberate acts, explained the collapses.
Campaigners hope the inquiry’s eventual publication will add independent weight to the medical evidence already before the CCRC.
Previous appeal outcomes
The Court of Appeal rejected Letby’s first appeal in 2024 and refused a second application later that year. Those rulings rested on the trial record as it stood, without the benefit of the new international reports.
The CCRC route exists precisely for cases where fresh evidence emerges after ordinary appeals have been exhausted, a procedural point now central to the current application.
Legal analysts note that the volume and specificity of the new material distinguish this review from earlier unsuccessful challenges.
International reactions
Medical journals and forensic specialists outside the United Kingdom have begun citing the Shoo Lee panel as a case study in contested expert evidence. Some commentators compare the situation to earlier UK miscarriages involving flawed pathology testimony.
Within the United States, true-crime audiences have followed the developments through BBC and Guardian reporting, drawing parallels to domestic cases where forensic reinterpretation led to exonerations.
No formal statements have come from U.S. medical bodies, yet the discussion has surfaced on professional listservs and academic podcasts focused on neonatal care standards.
Next procedural steps
The CCRC must decide whether the new evidence raises a real possibility that the Court of Appeal would quash the convictions. If it does, the case returns for fresh consideration; if not, the convictions stand.
Letby’s team continues to compile additional reports on unit practices and laboratory protocols while the commission’s review proceeds.
Any referral decision is expected to shape future debate over how statistical and medical evidence should be weighed in complex healthcare prosecutions.
Case status moving forward
The Lucy Letby convictions now rest on contested medical foundations that an international panel has rejected outright. The CCRC’s ongoing assessment will determine whether those findings are sufficient to reopen the case in court. Whatever the outcome, the volume of new expert material has already shifted the public record on the medical evidence presented at trial.
